Webcast ImageWebcast
Coherus Biosciences Inc at BMO Capital Markets 2016 Healthcare Conference (Live)
12/14/16 at 3:20 p.m. ET
Coherus Biosciences Inc at BMO Capital Markets 2016 Healthcare Conference
Wednesday, December 14, 2016 3:20 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar


Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

11/29/16Coherus’ Marketing Authorization Application to European Medicines Agency for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Accepted
REDWOOD CITY, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced acceptance of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate.  This represents the first EMA submission and acceptance for Coherus BioSciences. The CHS-1701 MAA is supported by biosimilarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies comparing ... 
11/17/16Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective November 17, 2016, the compensation committee of the company’s board of directors granted 6 new employees options to purchase an aggregate of 80,500 shares of the company’s common stock with a per share exercise price of $28.00, the closing trading price on the grant date.  In addition, 45,000 shares of stock were granted to a Vice President, Regulatory Affairs new hi... 
11/09/16Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results
Continued execution on multiple fronts positions the company strongly for the remainder of 2016 and beyond REDWOOD CITY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reported financial results and reviewed corporate events for the third quarter ended September 30, 2016. Corporate Highlights for the Third Quarter 2016 Include: Oncology therapeutic franchise: CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) U.S. Food and Drug... 
11/07/16Coherus BioSciences Receives Decision Denying Institution of the ‘166 IPR Related to AbbVie’s HUMIRA® Formulation
Management to host a call to discuss the decision REDWOOD CITY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office denying institution of Coherus’ petition for Inter Partes Review (IPR) of AbbVie’s U.S. Patent 9,114,166 (the “’166 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation.  “While we are disappointe... 
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.35 (1.27%)
Data as of 12/02/16 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet